1. Home
  2. MARPS vs BIAF Comparison

MARPS vs BIAF Comparison

Compare MARPS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marine Petroleum Trust Units of Beneficial Interest

MARPS

Marine Petroleum Trust Units of Beneficial Interest

N/A

Current Price

$4.51

Market Cap

9.2M

Sector

Energy

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

N/A

Current Price

$6.02

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MARPS
BIAF
Founded
1956
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
9.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
MARPS
BIAF
Price
$4.51
$6.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
7.3M
Earning Date
02-13-2026
05-14-2026
Dividend Yield
6.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
$14.39
N/A
Revenue Growth
N/A
14.49
52 Week Low
$4.05
$0.33
52 Week High
$6.49
$20.35

Technical Indicators

Market Signals
Indicator
MARPS
BIAF
Relative Strength Index (RSI) 44.74 51.30
Support Level $4.18 $1.27
Resistance Level $4.92 $20.35
Average True Range (ATR) 0.18 2.14
MACD -0.00 -0.20
Stochastic Oscillator 38.52 11.40

Price Performance

Historical Comparison
MARPS
BIAF

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: